Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: A combined in vitro and preclinical perspective
Authors:
Open Access
- 18 November 2024
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 377, 162-173
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Branching Ionizable Lipids Can Enhance the Stability, Fusogenicity, and Functional Delivery of mRNASmall Science, 2023
- In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacyBiomedicine & Pharmacotherapy, 2023
- The role of lipid components in lipid nanoparticles for vaccines and gene therapyAdvanced Drug Delivery Reviews, 2022
- Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle SizePharmaceutical Research, 2022
- The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatoryiScience, 2021
- Principles for designing an optimal mRNA lipid nanoparticle vaccineCurrent Opinion in Biotechnology, 2021
- Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugsDrug Metabolism and Pharmacokinetics, 2021
- PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM productionInternational Journal of Pharmaceutics, 2020
- Branched‐Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pHSmall, 2019
- The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide deliveryAdvanced Drug Delivery Reviews, 2016